– USA, MA – Odyssey Therapeutics, Inc., a biotechnology company pioneering next-generation precision immunomodulators for inflammatory diseases, today announced the appointments of Tim Walbert and Ian Smith to its Board of Directors bringing decades of senior leadership experience in building global biopharmaceutical companies.
“Tim’s legacy in the industry is hallmarked by the acquisition, development and commercialization of numerous life-changing therapies at Horizon that led to one of the largest biopharma acquisitions in recent years. Similarly, Ian was instrumental in evolving Vertex from its early stages into a global market leader – a testament to his financial acumen and ability to drive strategic growth,” said Board Chairman, Dr. Jeff Leiden.
About Timothy P. Walbert
Tim Walbert has more than 30 years of senior-level leadership and advisory expertise for global biopharmaceutical companies. For 15 years, he served as Chairman, President, and CEO of Horizon Therapeutics, where he oversaw the acquisition, development, and commercial launch of a dozen products for autoimmune and inflammatory diseases, leading to approximately $4 billion in net sales in 2023, and ultimately, Horizon’s $28.3 billion acquisition by Amgen the same year. He serves as a senior advisor to Amgen’s executive leadership and is a member of the Board of Directors for several companies, including COUR Pharmaceuticals, Sagimet Biosciences, Mirum Pharmaceuticals, and Century Therapeutics.
Tim Walbert was President, CEO, and Director of IDM Pharma and EVP of Commercial Operations at NeoPharm. Before that, as the Divisional VP and GM of Immunology at Abbott, Tim Walbertt led the development and launch of HUMIRA, a blockbuster product, and was also the Divisional VP of Global Cardiovascular Strategy. Earlier in his career, Tim Walbert held roles of increasing responsibility at G.D. Searle & Company, where he led the CELEBREX North America marketing team, as well as at Merck, Wyeth, and H.J. Heinz.
Tim Walbert received a Bachelor of Arts degree in business and marketing from Muhlenberg College in Pennsylvania.
About Ian F. Smith
Ian Smith is a 30-year industry veteran with deep expertise in corporate strategy, finance, and business development for biotech companies. Between 2001 and 2019, he served in various roles at Vertex, including as EVP COO, and CFO, where during his tenure, he was responsible for the financial strategy and operations of Vertex and played a core role in the company’s transition from a research-focused biotech to a multi-billion-dollar, global organization with market-leading products approved for chronic, life-shortening genetic diseases, including cystic fibrosis.
Ian Smith serves as Chairman of the Board of Directors of Rivus Pharmaceuticals and iVexSol, Executive Chairman of the Board of Solid Biosciences, and a member of the Board of Alkeus Pharmaceuticals, Foghorn Therapeutics, and Stoke Therapeutics.
Ian Smith received a Bachelor of Arts with honors in accounting and finance from Manchester Metropolitan University in England.
About Odyssey Therapeutics
Odyssey Therapeutics is a clinical-stage biotechnology company focused on discovering, developing, and commercializing the next generation of inflammatory precision medicines. Since its founding in 2021, Odyssey has rapidly advanced a pipeline of clinical- and research-stage programs, leveraging the scientific expertise of its team of drug hunters and a comprehensive suite of tools to tackle drug targets with the greatest potential to benefit patients. Odyssey’s mission is to create extraordinary leaps in patient outcomes and change the standard of care for those living with serious inflammatory diseases.
For more: https://odysseytx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.